Orphazyme A/S (OZYMF)
USD 90.0
(0.0%)
USD 90.0
(0.0%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 19.31 Million DKK | -66.02% |
| 2022 | 56.82 Million USD | 114.64% |
| 2021 | 26.47 Million DKK | -80.42% |
| 2020 | 135.2 Million DKK | 397.93% |
| 2019 | 27.15 Million DKK | -93.85% |
| 2018 | 441.34 Million DKK | -33.41% |
| 2017 | 662.81 Million DKK | 1975.13% |
| 2016 | 31.94 Million DKK | -62.4% |
| 2015 | 84.95 Million DKK | -10.9% |
| 2014 | 95.34 Million DKK | 168.1% |
| 2013 | 35.56 Million DKK | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 2.55 Million USD | 0.0% |
| 2023 Q1 | 36.18 Million DKK | -37.75% |
| 2023 Q2 | 36.18 Million USD | 0.0% |
| 2023 Q3 | 19.31 Million DKK | -46.62% |
| 2023 Q4 | 19.31 Million USD | 0.0% |
| 2023 FY | 19.31 Million DKK | -66.02% |
| 2022 Q2 | 13.14 Million DKK | -85.95% |
| 2022 Q4 | 58.12 Million USD | 2.28% |
| 2022 FY | 56.82 Million USD | 114.64% |
| 2022 Q1 | 93.58 Million DKK | -45.97% |
| 2022 Q3 | 56.82 Million DKK | 332.16% |
| 2021 Q1 | 428.03 Million DKK | -47.96% |
| 2021 Q2 | 428.03 Million DKK | 0.0% |
| 2021 Q3 | 173.22 Million DKK | -59.53% |
| 2021 Q4 | 173.22 Million DKK | 0.0% |
| 2021 FY | 26.47 Million DKK | -80.42% |
| 2020 Q1 | 676.36 Million DKK | 274.19% |
| 2020 FY | 135.2 Million DKK | 397.93% |
| 2020 Q4 | 822.49 Million DKK | 0.0% |
| 2020 Q2 | 676.36 Million DKK | 0.0% |
| 2020 Q3 | 822.49 Million DKK | 21.61% |
| 2019 Q3 | 180.75 Million DKK | -35.2% |
| 2019 Q4 | 180.75 Million DKK | 0.0% |
| 2019 Q1 | 278.92 Million DKK | -36.8% |
| 2019 Q2 | 278.92 Million DKK | 0.0% |
| 2019 FY | 27.15 Million DKK | -93.85% |
| 2018 Q4 | 441.34 Million DKK | 0.0% |
| 2018 FY | 441.34 Million DKK | -33.41% |
| 2018 Q2 | 544.37 Million DKK | 0.0% |
| 2018 Q1 | 544.37 Million DKK | -17.87% |
| 2018 Q3 | 441.34 Million DKK | -18.93% |
| 2017 Q3 | 662.81 Million DKK | 354.88% |
| 2017 FY | 662.81 Million DKK | 1975.13% |
| 2017 Q2 | 145.71 Million DKK | 0.0% |
| 2017 Q1 | 145.71 Million DKK | 356.19% |
| 2017 Q4 | 662.81 Million DKK | 0.0% |
| 2016 Q3 | 31.94 Million DKK | 0.0% |
| 2016 Q4 | 31.94 Million DKK | 0.0% |
| 2016 Q1 | - DKK | 0.0% |
| 2016 FY | 31.94 Million DKK | -62.4% |
| 2015 FY | 84.95 Million DKK | -10.9% |
| 2014 FY | 95.34 Million DKK | 168.1% |
| 2013 FY | 35.56 Million DKK | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 2310.00 USD | -835917.316% |
| Santhera Pharmaceuticals Holding AG | 130.21 Million USD | 85.169% |
| Neon Bloom, Inc. | 770.64 Thousand USD | -2405.956% |
| Nascent Biotech, Inc. | 552.12 Thousand USD | -3397.79% |
| Qrons Inc. | 420.00 USD | -4597995.238% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -5361.276% |
| Evofem Biosciences, Inc. | 10.55 Million USD | -82.983% |
| BioStem Technologies, Inc. | 14.56 Million USD | -32.635% |
| Skye Bioscience, Inc. | 11.94 Million USD | -61.736% |
| ProtoKinetix, Incorporated | 480.55 Thousand USD | -3918.67% |
| Rebus Holdings, Inc. | 5000.00 USD | -386140.0% |
| CSL Limited | 38.02 Billion USD | 99.949% |
| Northwest Biotherapeutics, Inc. | 27.94 Million USD | 30.89% |
| Capstone Therapeutics Corp. | 52.7 Million USD | 63.356% |
| Acro Biomedical Co., Ltd. | 687.48 Thousand USD | -2709.075% |
| Adynxx, Inc. | - USD | -Infinity% |
| Arch Therapeutics, Inc. | 1.95 Million USD | -886.217% |
| Eiger BioPharmaceuticals, Inc. | 38.84 Million USD | 50.287% |
| Nanobac Pharmaceuticals, Incorporated | 7.21 Million USD | -167.488% |
| Institute of Biomedical Research Corp. | 76.35 Thousand USD | -25192.716% |
| SQZ Biotechnologies Company | 107.18 Million USD | 81.983% |
| Intellipharmaceutics International Inc. | 1.43 Million USD | -1248.573% |
| Propanc Biopharma, Inc. | 72.36 Thousand USD | -26586.934% |
| Mesoblast Limited | 667.9 Million USD | 97.109% |
| Marizyme, Inc. | 22.01 Million USD | 12.278% |
| Genus plc | 1.02 Billion USD | 98.123% |
| VioQuest Pharmaceuticals, Inc. | 1.35 Million USD | -1321.722% |
| Pharming Group N.V. | 462.85 Million USD | 95.828% |
| Therapeutic Solutions International, Inc. | 3.31 Million USD | -482.914% |
| CNBX Pharmaceuticals Inc. | 499.03 Thousand USD | -3769.838% |
| Nymox Pharmaceutical Corporation | 627 Thousand USD | -2980.064% |
| ContraFect Corporation | 20.67 Million USD | 6.611% |
| PsyBio Therapeutics Corp. | 390.36 Thousand USD | -4847.152% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 382.17 Thousand USD | -4953.156% |
| IMV Inc. | 31.33 Million USD | 38.367% |
| AXIM Biotechnologies, Inc. | 4.14 Million USD | -365.796% |
| MultiCell Technologies, Inc. | 126.22 USD | -15300169.371% |
| ONE Bio Corp. | 70.08 Million USD | 72.445% |
| Accustem Sciences Inc. | 939.68 Thousand USD | -1955.148% |
| RVL Pharmaceuticals plc | 128.51 Million USD | 84.972% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 431.71 Thousand USD | -4373.332% |
| Q BioMed Inc. | 3.51 Million USD | -449.336% |
| Emmaus Life Sciences, Inc. | 35.17 Million USD | 45.104% |
| Mosaic ImmunoEngineering Inc. | 261.27 Thousand USD | -7291.389% |
| Biomind Labs Inc. | 73.81 Thousand USD | -26061.286% |
| American Oriental Bioengineering, Inc. | 446.3 Million USD | 95.673% |
| Provectus Biopharmaceuticals, Inc. | 1.44 Million USD | -1232.926% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 30.01 Million USD | 35.659% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | 2.74 Million USD | -603.192% |
| Curative Biotechnology, Inc. | 2.6 Million USD | -641.857% |
| GB Sciences, Inc. | 103.44 Thousand USD | -18569.399% |
| Alpha Cognition Inc. | 2.45 Million USD | -687.547% |
| HST Global, Inc. | 1526.00 USD | -1265430.799% |
| Wesana Health Holdings Inc. | 987.96 Thousand USD | -1854.721% |
| Halberd Corporation | 10.13 Thousand USD | -190522.841% |
| Enzolytics Inc. | 361.7 Million USD | 94.661% |
| Agentix Corp. | 261.39 Thousand USD | -7288.137% |
| Resverlogix Corp. | 8.11 Million USD | -137.979% |
| Nuo Therapeutics, Inc. | 1.87 Million USD | -928.394% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 4.54 Billion USD | 99.575% |
| Enzon Pharmaceuticals, Inc. | 47.7 Million USD | 59.515% |
| Endonovo Therapeutics, Inc. | 639.65 Thousand USD | -2919.123% |
| RespireRx Pharmaceuticals Inc. | 22.78 Thousand USD | -84672.398% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 8.94 Million USD | -115.797% |
| AVAX Technologies, Inc. | 7.37 Million USD | -161.781% |
| Zenith Capital Corp. | 7410.00 USD | -260520.783% |
| Genscript Biotech Corporation | 3.38 Billion USD | 99.43% |
| Ember Therapeutics, Inc. | 184.00 USD | -10495552.174% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 321.8 Thousand USD | -5901.131% |
| WPD Pharmaceuticals Inc. | 261.36 Thousand USD | -7288.929% |
| Cotinga Pharmaceuticals Inc. | 927.96 Thousand USD | -1981.122% |
| Kadimastem Ltd | 2.3 Million USD | -738.165% |
| Helix BioMedix, Inc. | 3.02 Million USD | -538.395% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 57.09 Thousand USD | -33724.92% |
| LadRx Corporation | 2.3 Million USD | -736.785% |
| Cell Source, Inc. | 195.17 Thousand USD | -9794.913% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -5361.276% |
| NovAccess Global Inc. | 62.24 Thousand USD | -30924.29% |
| Affymax, Inc. | 7.44 Million USD | -159.465% |
| Itoco Inc. | 1.4 Million USD | -1279.358% |
| Rasna Therapeutics, Inc. | 95.65 Thousand USD | -20088.8% |
| Pathfinder Cell Therapy, Inc. | 106 Thousand USD | -18118.868% |
| Mobile Lads Corp. | 52.00 USD | -37138361.538% |
| CytoDyn Inc. | 11.13 Million USD | -73.42% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 142.97 Thousand USD | -13407.54% |
| NanoSphere Health Sciences Inc. | 17.88 Thousand USD | -107908.949% |
| Alseres Pharmaceuticals, Inc. | 385.47 Thousand USD | -4909.975% |
| SYBLEU INC | 330.46 Thousand USD | -5743.834% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 409.42 Thousand USD | -4616.894% |
| International Stem Cell Corporation | 5.39 Million USD | -258.293% |
| Bioxytran, Inc. | 137.63 Thousand USD | -13931.009% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 15 Million USD | -28.731% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 16.57 Million USD | -16.485% |
| Adhera Therapeutics, Inc. | 79 Thousand USD | -24345.57% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 864.67 Thousand USD | -2133.435% |
| Innovation Pharmaceuticals Inc. | 7.51 Million USD | -156.911% |
| Neutra Corp. | 2851.00 USD | -677276.359% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | 40.406% |
| PureTech Health plc | 693.97 Million USD | 97.217% |
| Coeptis Therapeutics, Inc. | 8.07 Million USD | -139.274% |
| IXICO plc | 15.84 Million USD | -21.889% |
| IntelGenx Technologies Corp. | 8.28 Million USD | -133.18% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 81.309% |
| CSL Limited | 38.02 Billion USD | 99.949% |
| Cellectis S.A. | 333.99 Million USD | 94.218% |